See more : Shalby Limited (SHALBY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of VistaGen Therapeutics, Inc. (VTGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VistaGen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sustainable Development Acquisition I Corp. (SDAC) Income Statement Analysis – Financial Results
- EDION Corporation (2730.T) Income Statement Analysis – Financial Results
- China Railway Prefabricated Construction Co., Ltd. (300374.SZ) Income Statement Analysis – Financial Results
- EyeGate Pharmaceuticals, Inc. (EYEG) Income Statement Analysis – Financial Results
- Da Ming International Holdings Limited (1090.HK) Income Statement Analysis – Financial Results
VistaGen Therapeutics, Inc. (VTGN)
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 103.10K | 91.20K | 80.70K | 0.00 | 53.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 20.02M | 44.38M | 35.41M | 11.93M | 13.37M | 17.10M | 7.76M | 5.20M | 3.93M | 2.43M | 2.48M | 3.43M | 5.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.06M | 14.66M | 10.45M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.39K | 21.54K | 16.35K | 4.78K |
| Selling & Marketing | 0.00 | 1.90M | 2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.06M | 14.66M | 13.25M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.52K | 21.54K | 16.35K | 4.78K |
| Other Expenses | 0.00 | 0.00 | 232.00K | -400.00 | -827.00K | -48.70K | -428.00K | 426.80K | -2.30K | -233.00K | 0.00 | 0.00 | 641.00K | 428.00 | 428.00 | 36.00 | 0.00 |
| Operating Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Cost & Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Interest Income | 0.00 | 49.00K | 20.00K | 15.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 10.00K | 30.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 23.00K | 0.00 | 13.00K | 15.00K | 8.00K | 8.90K | 5.00K | 777.00K | 4.62M | 1.56M | 1.00M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 568.00K | 532.00K | 711.10K | 477.60K | 103.10K | 91.20K | 80.70K | 54.90K | 53.50K | 59.10K | 54.60K | 33.80K | 45.60K | 428.00 | 428.00 | 36.00 | 0.00 |
| EBITDA | -32.45M | -58.74M | -47.05M | -17.44M | -20.65M | -24.47M | -14.25M | -9.77M | -17.80M | -6.72M | -4.97M | -11.85M | -10.27M | -6.32M | -21.54K | -16.35K | -4.78K |
| EBITDA Ratio | -3,050.09% | 25,816.45% | -4,221.83% | -1,633.87% | 0.00% | 0.00% | 0.00% | -815.46% | 0.00% | 0.00% | 0.00% | -3,340.62% | -670.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.02M | -59.27M | -47.78M | -17.93M | -20.80M | -24.56M | -14.20M | -10.25M | -17.85M | -6.78M | -5.03M | -6.79M | -9.04M | -8.95K | -21.97K | -16.39K | -4.78K |
| Operating Income Ratio | -3,103.48% | 26,040.74% | -4,308.68% | -1,646.06% | 0.00% | 0.00% | 0.00% | -819.88% | 0.00% | 0.00% | 0.00% | -3,389.77% | -673.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.66M | 26.00K | 19.90K | 2.20K | 30.10K | -30.70K | -143.90K | -4.60K | -29.37M | -7.11M | 2.06M | -6.09M | -3.16M | -9.47M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -29.36M | -59.24M | -47.76M | -17.93M | -20.77M | -24.59M | -14.34M | -10.25M | -47.22M | -13.88M | -2.97M | -12.88M | -12.21M | -8.95K | -21.97K | -16.39K | -4.78K |
| Income Before Tax Ratio | -2,759.21% | 26,063.26% | -4,306.88% | -1,645.86% | 0.00% | 0.00% | 0.00% | -820.25% | 0.00% | 0.00% | 0.00% | -6,428.64% | -909.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00K | 6.00K | 3.40K | 2.60K | 2.60K | 2.60K | 2.40K | 2.40K | 2.30K | 2.40K | 2.70K | 3.70K | 1.60K | 30.00 | 30.00 | 30.00 | -30.00 |
| Net Income | -29.36M | -59.25M | -47.76M | -17.93M | -20.77M | -24.59M | -14.35M | -10.26M | -47.22M | -13.89M | -2.97M | -12.89M | -12.21M | -8.98K | -22.00K | -16.42K | -4.75K |
| Net Income Ratio | -2,759.59% | 26,065.86% | -4,307.19% | -1,646.09% | 0.00% | 0.00% | 0.00% | -820.44% | 0.00% | 0.00% | 0.00% | -6,430.49% | -909.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.28 | -318.27 | -74.47 | -426.99 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| EPS Diluted | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.27 | -315.87 | -81.00 | -426.98 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| Weighted Avg Shares Out | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.63K | 39.85K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
| Weighted Avg Shares Out (Dil) | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.96K | 36.64K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
Vistagen to Present at the Stifel 2024 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place...
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino...
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate...
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for...
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific...
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to...
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a...
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject...
Source: https://incomestatements.info
Category: Stock Reports